in Wauwatosa has been named the third-best children's hospital in the nation by Parents magazine.
Parents magazine Monday revealed the exclusive findings from its 10 Best Children’s Hospitals survey. The Children’s Hospital of Philadelphia ranked first in the survey, while Children's Hospital Boston ranked second.
Five specialty programs at Children's Hospital of Wisconsin were rated in the top 10: emergency care ranked Read the rest of this entry »
(CAH) lowered its fiscal-year earnings outlook, as the
medical-supply and pharmaceutical company suffers from customers deferring
capital spending.
Cardinal warned last month it was monitoring such expenditures, which the
company had called a key variable for projected results.
R. Kerry Clark
said Thursday “it is difficult to
forecast the exact duration and potential long-term changes in hospital spending
patterns.” But medical-products chief
Read the rest of this entry »
Last week the FDA announced that fibrinogen concentrate
had been granted licensing as an orphan drug for the treatment of bleeding in
patients with congenital fibrinogen deficiency.
Patients with this disorder are unable to make
sufficient amounts of fibrinogen. It affects between 150 and 300 people in the
United States and is usually diagnosed at birth when bleeding occurs from the
umbilical cord site.
IV fibrinogen concentrate Read the rest of this entry »
The less common form of MS — primary progressive — doesn’t manifest itself with acute attacks, although patients still exhibit neurodegeneration, leading to fatigue, pain, problems with walking and balance, dizziness and bladder and bowel dysfunction.
Currently approved drugs primarily work by reducing the activity of lymphocytes or reducing their ability to travel from the blood into the nervous system. Some of the new ones do that too — while Read the rest of this entry »
Inc. is due to appear Monday before outside medical experts and Food and Drug Administration officials to make a case for allowing its Fablyn osteoporosis drug on the market. It will be the drug’s third go-round, and approval is important for a pharmaceutical company that, like its rivals, is eager to fill its new-product pipeline.
In briefing documents posted ahead of the meeting, the FDA said patients taking Fablyn were at a lower risk of developing Read the rest of this entry »
January 25, 2009 – January 31, 2009
January 18, 2009 – January 24, 2009
January 11, 2009 – January 17, 2009
January 4, 2009 – January 10, 2009
December 28, 2008 – January 3, 2009
December 21, 2008 – December 27, 2008
December 14, 2008 – December 20, 2008
December 7, 2008 – December 13, 2008
November 30, 2008 – December 6, 2008
November 23, 2008 – November 29, 2008
November 16, 2008 – November 22, 2008
November 9, 2008 – November Read the rest of this entry »
…a bolderific political performance by the standards of national media watching with jaws hanging. But pretty ordinary fare by the standards of
wrongdoing of one kind or another.
(“I did not have sex with that woman”), Blagojevich carefully avoided providing colorful reusable video denials. He also purposefully didn’t mention his nomination of fellow Democrat
to fill the state’s U.S. Senate vacancy; that slick move is proceeding on a separate Read the rest of this entry »
OSTON – Health insurer Blue Cross and Blue Shield of Massachusetts is trying to cut costs in anticipation more competition in the marketplace and a drop in enrollment.
The Boston Globe, citing an internal company e-mail, reports Friday that the state’s largest health insurer is not planning layoffs, but wants to reduce staff through attrition, boost productivity through the use of technology, and allow more employees to work from home to save Read the rest of this entry »
Associated Press
10.17.08,
8:53 AM ET
CHAPEL HILL, N.C. -
Pozen Inc.
that they are reviewing the acceptability of using endoscopic gastric ulcers as the main goal of clinical studies, the drug developer said Friday.
Pozen is developing two drugs, including PA32540, which is designed to have the cardiovascular benefits of aspirin with a lower rate of patient ulcers. PN 400 is a combination of the pain reliever naproxen and the acid Read the rest of this entry »
ZURICH -(Dow Jones)- Pharmaceutical giant Novartis AG (NVS) said Tuesday its experimental drug RAD001 has been granted priority review by the U.S. Food and Drug Administration for approval as treatment for advanced kidney cancer, paving the way for possible approval early next year.
Novartis, based in Basel, Switzerland, said the filing of the drug was based on a late-stage study which showed treatment with the drug on average extended the time Read the rest of this entry »